Sandra Horning, MD
Adding atezolizumab (Tecentriq) to pemetrexed (Alimta) and cisplatin or carboplatin in the frontline setting reduced the risk of disease progression or death versus chemotherapy alone in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), according to findings from the phase III IMpower132 study.
In a comment posted today on Twitter, H. “Jack” West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, said that the IMpower132 trial had a “similar design as KEYNOTE-189, achieving PFS but not OS benefit (at least not yet). Comparing to [KEYNOTE]-189, IMpower132 falls short [without] OS benefit.”
... to read the full story